Dimebutic Acid

Dimebutic Acid

SCHEMBL1176121

CCC(C)(C)C(=O)[O-].[Na+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Dimebutic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1056 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4736257-A1 METHOD FOR DISMANTLING BATTERIES, INVOLVING DEEP DISCHARGING AND ENERGY RECOVERY SUEZ International (FR) 2026-05-06 EP claimed
US-20260021186-A1 Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-01-22 US claimed
EP-4389463-B1 METHOD AND DEVICE FOR DETERMINING TIRE WEARS TOYOTA MOTOR CO LTD (JP) 2025-08-20 EP claimed
CN-120163839-A Iris rapid and accurate segmentation method based on target detection 温州市人民医院 2025-06-17 CN claimed
CN-120164360-A Lumbar puncture training system 温州市人民医院 2025-06-17 CN claimed
EP-4565325-A2 FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-11 EP claimed
CN-120031179-A Instrument sharing platform operation success prediction method based on machine learning algorithm 浙江农林大学 2025-05-23 CN claimed
CN-119855613-A Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders 匹兹堡大学高等教育联邦体系 2025-04-18 CN claimed
EP-4536256-A2 PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Siolta Therapeutics, Inc. (US) 2025-04-16 EP claimed
CN-119828580-A Automatic compensation control system for treating wire rod iron scale 贵州航天南海科技有限责任公司 2025-04-15 CN claimed
WO-2016196281-A1 MTAP INHIBITORS FOR THE TREATMENT OF SICKLE CEMTAP DISEASE NANOMETICS LLC (US) 2016-12-08 WO claimed
WO-2015127163-A1 PYRIDOXAMINE FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA AND RELATED BLOOD DISEASES PHD BIOSCIENCES ( FORMERLY NANOMETICS LLC) (US) 2015-08-27 WO claimed
US-8618068-B2 Methods and low dose regimens for treating red blood cell disorders TRUSTEES OF BOSTON UNIVERSITY (US) 2013-12-31 US claimed
EP-2509418-A1 METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS Hemaquest Pharmaceuticals, Inc. (US) 2012-10-17 EP claimed
WO-2011072086-A9 METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS HEMAQUEST PHARMACEUTICALS, INC. (US) 2012-09-27 WO claimed
EP-2380571-A1 BIOSYNTHESIS OF DERIVATIVES OF MONACOLIN J Neuron Biopharma, S.A. (ES) 2011-10-26 EP claimed
US-20110251149-A1 METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS TRUSTEES OF BOSTON UNIVERSITY (US) 2011-10-13 US claimed
US-20110189726-A1 BIOSYNTHESIS OF DERIVATIVES OF MONACOLIN J NEURON BIOPHARMA, S.A. (ES) 2011-08-04 US claimed
WO-2011072086-A1 METHODS AND LOW DOSE REGIMENS FOR TREATING RED BLOOD CELL DISORDERS HEMAQUEST PHARMACEUTICALS, INC. (US) 2011-06-16 WO claimed
US-7265153-B2 Compositions and methods for the treatment of cystic fibrosis TRUSTEES OF BOSTON UNIVERSITY 2007-09-04 US claimed